Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system.
Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.
Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patient's overall health.
There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.
Key Market Movements:
- Rising prevalence of leukemia is expected to assist the hematopoietic stem cells transplantation as the survival rates in leukemia patients has been improved after HSCT.
- Future opportunity for HSCT market lies in regenerative Stromal Cell Therapy because it is considered as one of the novel therapies for prevention and treatment of acute graft versus host disease in allogeneic HSCT patients.
- In emerging economies growing government support through providing favorable environments for research laboratories in the field of stem cell research
- CellGenix Technologie Transfer GmbH
- Cesca Therapeutics Inc.
- Escape Therapeutics
- Kite Pharma Inc.
- Lonza Group
- Pluristem Therapeutics Inc.
- PromoCell GmbH
- R&D Systems
- ScienCell Research Laboratories
- Stempuetics Research Pvt. Ltd.
- Takara Bio
- Thermo Fisher Scientific, Inc.
- TiGenix N.V.
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Hematopoietic Stem Cells Transplantation Market Overview
Chapter 4 Global Hematopoietic Stem Cells Transplantation Market Analysis, By Transplant Type
Chapter 5 Global Hematopoietic Stem Cells Transplantation Market Analysis, By Applications
Chapter 6 Global Hematopoietic Stem Cells Transplantion Market, By Geography
Chapter 7 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/zlrj7b/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-hematopoietic-stem-cells-transplantation-market-analysis---trends-technologies--opportunities-report-2012-2022---vendors-tigenix-rd-systems-kite-pharma-300364119.html
SOURCE Research and Markets